Fulcrum Therapeutics (FULC) Cash from Financing Activities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Cash from Financing Activities data on file, last reported at -$312000.0 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to -$312000.0 in Q1 2026; TTM through Mar 2026 was $168.4 million, a 15274.89% increase from a year earlier, with the FY2025 full-year figure at $168.7 million, up 6042.28% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$312000.0, down from $168.3 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for FULC reached as high as $168.3 million in Q4 2025 and fell as low as -$312000.0 in Q1 2026.
• Historically, Cash from Financing Activities has averaged $24.9 million across 5 years, with a median of $348000.0 in 2022.
• Across the five-year window, Cash from Financing Activities sank 99.27% in 2022 and jumped 202673.49% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $218000.0 in 2022, then jumped by 31.65% to $287000.0 in 2023, then slumped by 71.08% to $83000.0 in 2024, then soared by 202673.49% to $168.3 million in 2025, then tumbled by 100.19% to -$312000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$312000.0 in Q1 2026, $168.3 million in Q4 2025, and $64000.0 in Q3 2025.